MGM IPO, WHEN?

Macau market growth has been outstanding but MGM continues to underperform. What will this mean for the timing of the MGM Macau IPO? 

 

 

We think MGM may have to delay its planned IPO.  As of MGM's last conference call, management had expected to price the IPO in late Q3/early Q4.  While the timing may seem good given that growth in the Macau market has been off the charts and investor sentiment is pretty positive, MGM Macau has been a laggard.  See the market share chart below.  The trend in MGM's market share doesn't look good on its own given the property's size and lately, has been significantly below its share of table games.  Fair share is not where it should be. 

 

MGM IPO, WHEN? - mgm3

 

MGM needs to sell this deal on a future level of EBITDA significantly higher than the trailing four quarters tally of $205 million. One way to do that would be to increase market share.  We believe they have taken a step in that direction with the hiring of Mr. Kwong to run the VIP business.  As we pointed out last week in our note "MGM LOOKING TO BOOST VIP SHARE, " Mr. Kwong is a top line focused operator with significant junket connections.  He should bring over a big book of business.   He's not afraid of sacrificing the bottom line to help the top line but MGM may not be interested in near-term profits.  The problem is that Kwong doesn't start until September and will need a few months to prove his mettle. 

 

The second timing issue MGM faces concerns Grant Bowie.  His contract runs out this year and we're not sure Pansy Ho nor MGM may be keen to renew the contract.  Thus, the new GM would need time to implement his plan and show results.  These hurdles may push the timing at least into Q1 2011, maybe later.


GOLD: A Deep Dive on What’s Next with a Top Commodities Strategist

“If you saved in gold over the past 20 to 25 years rather than any currency anywhere in the world, gold has outperformed all these currencies,” says Stefan Wieler, Vice President of Goldmoney in this edition of Real Conversations.

read more

Exact Sciences Up +24% This Week... What's Next? | $EXAS

We remain long Exact Sciences in the Hedgeye Healthcare Position Monitor.

read more

Inside the Atlanta Fed's Flawed GDP Tracker

"The Atlanta Fed’s GDPNowcast model, while useful at amalgamating investor consensus on one singular GDP estimate for any given quarter, is certainly not the end-all-be-all of forecasting U.S. GDP," writes Hedgeye Senior Macro analyst Darius Dale.

read more

Cartoon of the Day: Acrophobia

"Most people who are making a ton of money right now are focused on growth companies seeing accelerations," Hedgeye CEO Keith McCullough wrote in today's Early Look. "That’s what happens in Quad 1."

read more

People's Bank of China Spins China’s Bad-Loan Data

PBoC Deputy Governor Yi says China's non-performing loan problem has “pretty much stabilized." "Yi is spinning. China’s bad-debt problem remains serious," write Benn Steil and Emma Smith, Council on Foreign Relations.

read more

UnderArmour: 'I Am Much More Bearish Than I Was 3 Hours Ago'

“The consumer has a short memory.” Yes, Plank actually said this," writes Hedgeye Retail analyst Brian McGough. "Last time I heard such arrogance was Ron Johnson."

read more

Buffalo Wild Wings: Complacency & Lack of Leadership (by Howard Penney)

"Buffalo Wild Wings has been plagued by complacency and a continued lack of adequate leadership," writes Hedgeye Restaurants analyst Howard Penney.

read more

Todd Jordan on Las Vegas Sands Earnings

"The quarter actually beat lowered expectations. Overall, the mass segment performed well although base mass lagging is a concern," writes Hedgeye Gaming, Lodging & Leisure analyst Todd Jordan on Las Vegas Sands.

read more

An Update on Defense Spending by Lt. Gen Emo Gardner

"Congress' FY17 omnibus appropriation will fully fund the Pentagon's original budget request plus $15B of its $30B supplemental request," writes Hedgeye Potomac Defense Policy analyst Lt. Gen Emerson "Emo" Gardner USMC Ret.

read more

Got Process? Zero Hedge Sells Fear, Not Truth

Fear sells. Always has. Look no further than Zero Hedge.

read more

REPLAY: Review of $EXAS Earnings Call (A Hedgeye Best Idea Long)

Our Healthcare Team made a monster call to be long EXAS - hear their updated thoughts.

read more

Capital Brief: 5 Things to Watch Right Now In Washington

Here's a quick look at some key issues investors should keep an eye on from Hedgeye's JT Taylor and our team of Washington Policy analysts in D.C.

read more